In a world obsessed with flashy SaaS valuations, LipoCoat is quietly printing €3.3M in revenue by solving the most critical problem in medical devices: what happens when biology meets synthetic materials. They're not building apps—they're building the molecular interface that keeps your heart stent from being rejected by your body.

"They don't compete on features—they compete on biocompatibility. And that's a moat no SaaS startup can copy."

The tech stack tells another story: jQuery, Bootstrap, and Chart.js—this isn't a venture-funded rocket ship burning cash on Web3 nonsense. This is a pragmatic, engineering-first company building for longevity. They use Tailwind for speed, Analytics for precision, and they're not wasting cycles on bleeding-edge frameworks. That's the kind of discipline that turns €3.3M into €33M.

• Bio-inspired coatings that make medical devices invisible to immune systems
• Serving healthcare, pharma, and medical device giants—three industries that never cut corners
• Capital-efficient model: 21 people, €3.3M revenue, zero vanity metrics